Literature DB >> 8589441

Dystroglycan mRNA expression during normal and mdx mouse embryogenesis: a comparison with utrophin and the apo-dystrophins.

J N Schofield1, D C Górecki, D J Blake, K Davies, Y H Edwards.   

Abstract

Alpha dystroglycan (156 kDa DAG) and beta dystroglycan (43 kDa DAG) are encoded by the same gene and are components of the dystrophin-associated membrane glycoprotein complex. The dystroglycans together with dystrophin form a link between the extracellular matrix and the intracellular cytoskeleton of the muscle fibre. Using in situ hybridisation to mRNA in embryo sections we have examined the expression of the mouse dystroglycan gene. Dystroglycan transcripts are ubiquitously expressed throughout development but are most abundant in cardiac, skeletal and smooth muscle and in ependymal cells lining the developing neural tube and brain. The expression patterns of dystroglycan and dystrophin overlap in major muscle systems during development, suggesting that the dystrophin-dystroglycan complex plays an important role during myogenesis. In contrast, the major sites of utrophin expression do not co-localize with those of dystroglycan suggesting that utrophin may interact with a distinct membrane-associated complex in these non-muscle sites. In mdx embryos the pattern of distribution of dystroglycan mRNA remains unchanged, as do those of utrophin and apo-dystrophin mRNAs. This observation implies that the observed changes in the relative abundance of DAGs and utrophin in dystrophin-deficient muscle occur post-transcriptionally.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589441     DOI: 10.1002/aja.1002040208

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  10 in total

Review 1.  Hanging on for the ride: adhesion to the extracellular matrix mediates cellular responses in skeletal muscle morphogenesis and disease.

Authors:  Michelle F Goody; Roger B Sher; Clarissa A Henry
Journal:  Dev Biol       Date:  2015-01-12       Impact factor: 3.582

2.  Evidence of an agrin receptor in cortical neurons.

Authors:  L G Hilgenberg; C L Hoover; M A Smith
Journal:  J Neurosci       Date:  1999-09-01       Impact factor: 6.167

3.  Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation.

Authors:  Deborah Merrick; Lukas Kurt Josef Stadler; Dean Larner; Janet Smith
Journal:  Dis Model Mech       Date:  2009-06-17       Impact factor: 5.758

4.  Dystrobrevin and dystrophin family gene expression in zebrafish.

Authors:  Sabrina Böhm; Hong Jin; Simon M Hughes; Roland G Roberts; Yaniv Hinits
Journal:  Gene Expr Patterns       Date:  2007-10-24       Impact factor: 1.224

Review 5.  Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.

Authors:  Christine Péladeau; Bernard J Jasmin
Journal:  RNA Biol       Date:  2020-11-19       Impact factor: 4.652

6.  Second-generation compound for the modulation of utrophin in the therapy of DMD.

Authors:  Simon Guiraud; Sarah E Squire; Benjamin Edwards; Huijia Chen; David T Burns; Nandini Shah; Arran Babbs; Stephen G Davies; Graham M Wynne; Angela J Russell; David Elsey; Francis X Wilson; Jon M Tinsley; Kay E Davies
Journal:  Hum Mol Genet       Date:  2015-05-01       Impact factor: 6.150

7.  Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression.

Authors:  Angelina M Georgieva; Xinyue Guo; Marek Bartkuhn; Stefan Günther; Carsten Künne; Christian Smolka; Ann Atzberger; Ulrich Gärtner; Kamel Mamchaoui; Eva Bober; Yonggang Zhou; Xuejun Yuan; Thomas Braun
Journal:  Nat Commun       Date:  2022-07-20       Impact factor: 17.694

8.  Laminin α2 controls mouse and human stem cell behaviour during midbrain dopaminergic neuron development.

Authors:  Maqsood Ahmed; Leandro N Marziali; Ernest Arenas; M Laura Feltri; Charles Ffrench-Constant
Journal:  Development       Date:  2019-08-29       Impact factor: 6.868

9.  Non-invasive tracking of disease progression in young dystrophic muscles using multi-parametric MRI at 14T.

Authors:  Joshua S Park; Ravneet Vohra; Thomas Klussmann; Niclas E Bengtsson; Jeffrey S Chamberlain; Donghoon Lee
Journal:  PLoS One       Date:  2018-10-26       Impact factor: 3.752

10.  Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.

Authors:  Simon Guiraud; Benjamin Edwards; Sarah E Squire; Lee Moir; Adam Berg; Arran Babbs; Nesrine Ramadan; Matthew J Wood; Kay E Davies
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 6.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.